Quidel Co. (NASDAQ:QDEL) Director Charles P. Slacik sold 1,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $55.19, for a total transaction of $55,190.00. Following the transaction, the director now owns 8,703 shares of the company’s stock, valued at approximately $480,318.57. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of QDEL traded up $0.71 during midday trading on Friday, hitting $55.13. The stock had a trading volume of 14,038 shares, compared to its average volume of 221,240. Quidel Co. has a fifty-two week low of $44.27 and a fifty-two week high of $77.63. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 0.82 and a beta of 1.31. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.33 and a quick ratio of 0.91.

Quidel (NASDAQ:QDEL) last announced its earnings results on Wednesday, May 8th. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.98 by ($0.14). Quidel had a return on equity of 25.33% and a net margin of 12.98%. The firm had revenue of $148.00 million during the quarter, compared to analyst estimates of $157.61 million. During the same quarter in the previous year, the business earned $1.29 earnings per share. The business’s quarterly revenue was down 12.5% compared to the same quarter last year. Analysts anticipate that Quidel Co. will post 2.72 earnings per share for the current year.

QDEL has been the subject of several research reports. BidaskClub lowered shares of Quidel from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 5th. Zacks Investment Research upgraded shares of Quidel from a “hold” rating to a “buy” rating and set a $65.00 price objective for the company in a research report on Tuesday, February 5th. ValuEngine upgraded shares of Quidel from a “hold” rating to a “buy” rating in a research report on Friday, February 8th. Barclays restated a “buy” rating and set a $74.00 price objective on shares of Quidel in a research report on Friday, February 15th. Finally, Craig Hallum raised their price objective on shares of Quidel from $51.00 to $63.00 and gave the company a “hold” rating in a research report on Thursday, February 14th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $72.83.

Institutional investors and hedge funds have recently made changes to their positions in the business. Rothschild & Co. Asset Management US Inc. boosted its holdings in shares of Quidel by 1.2% in the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 454,933 shares of the company’s stock worth $22,210,000 after buying an additional 5,311 shares during the period. Bowling Portfolio Management LLC acquired a new position in shares of Quidel in the fourth quarter worth about $391,000. Mackay Shields LLC acquired a new position in shares of Quidel in the fourth quarter worth about $1,039,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Quidel by 22.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 407,887 shares of the company’s stock worth $19,913,000 after buying an additional 74,284 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Quidel by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 387,877 shares of the company’s stock worth $18,936,000 after buying an additional 27,954 shares during the period. Institutional investors own 88.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://theolympiareport.com/2019/05/24/charles-p-slacik-sells-1000-shares-of-quidel-co-qdel-stock.html.

Quidel Company Profile

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Featured Article: Federal Reserve

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.